Full name

The ENDURA-1 Study: A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab In Adult Participants With COPD With Type 2 Inflammation

NCT Number
NCT06959095
Geography
US
Locations

United States

Primary Endpoints

Annualized Rate of Moderate/Severe Exacerbations. Baseline up to Week 104

Order
1
Disease
Menu title
ENDURA-1: Depemokimab as an Extended treatmeNt Duration Biologic in Adults with Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
Version
Phase
3
Status
Recruiting